证券出售报告
Cymabay Therapeutics(CBAY)01-30 07:05
$Cymabay Therapeutics(CBAY)$ 144 Report of proposed sale of securities Accession Number: 0001972362-24-000050 Act: 33 Size: 6 KB 网页链接
简介：Cymabay Therapeutics, Inc.于1988年10月5日根据特拉华州的法律注册成立。CymaBay 治疗公司专注于开发治疗代谢和有大量需求的罕见疾病的疗法。其先导候选产品Arhalofenate，目前正在开发用于治疗痛风。Arhalofenate已经在痛风患者和一贯表现为有能力减少痛风发作和降低血清尿酸的患者中成功完成第三阶段的临床试验。
| 今开： | 昨收：32.48 |
| 最高： | 最低： |
| 涨停价： | 跌停价： |
| 总市值：3726247895 |
Cymabay Therapeutics(CBAY)01-30 07:05
$Cymabay Therapeutics(CBAY)$ 144 Report of proposed sale of securities Accession Number: 0001972362-24-000050 Act: 33 Size: 6 KB 网页链接
Cymabay Therapeutics(CBAY)02-13 06:35
$Cymabay Therapeutics(CBAY)$ SC14D9C Written communication relating to third party tender offer Accession Number: 0001193125-24-032309 Act: 34 Size: 312 KB 网页链接
Cymabay Therapeutics(CBAY)01-31 07:35
$Cymabay Therapeutics(CBAY)$ 144 Report of proposed sale of securities Accession Number: 0001972362-24-000053 Act: 33 Size: 7 KB 网页链接
美股滚雪球02-27 11:25
并购要趁早，不然股价涨上来了，要价就高了，比如$吉利德科学(GILD)$ 与$Cymabay Therapeutics(CBAY)$ ：
November 20: GILD offers $23.00/share
January 25: GILDoffers $31.00/share plus a CVR of up to $2.50/share
January 30: GILD offers $32.50/share，January 31: CBAY ask...
Cymabay Therapeutics(CBAY)01-27 05:15
$Cymabay Therapeutics(CBAY)$ 8-K Current report, items 5.02 and 9.01 Accession Number: 0001193125-24-016706 Act: 34 Size: 150 KB 网页链接
Cymabay Therapeutics(CBAY)03-23 04:45
$Cymabay Therapeutics(CBAY)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-24-075358 Act: 33 Size: 36 KB 网页链接
Cymabay Therapeutics(CBAY)03-23 04:55
$Cymabay Therapeutics(CBAY)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-24-075399 Act: 33 Size: 36 KB 网页链接
Cymabay Therapeutics(CBAY)03-23 04:55
$Cymabay Therapeutics(CBAY)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-24-075382 Act: 33 Size: 36 KB 网页链接
Cymabay Therapeutics(CBAY)03-23 05:05
$Cymabay Therapeutics(CBAY)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-24-075403 Act: 33 Size: 36 KB 网页链接
Cymabay Therapeutics(CBAY)02-29 05:45
$Cymabay Therapeutics(CBAY)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001193125-24-050758 Act: 34 Size: 11 MB 网页链接
美股滚雪球02-27 11:25
并购要趁早，不然股价涨上来了，要价就高了，比如$吉利德科学(GILD)$ 与$Cymabay Therapeutics(CBAY)$ ：
November 20: GILD offers $23.00/share
January 25: GILDoffers $31.00/share plus a CVR of up to $2.50/share
January 30: GILD offers $32.50/share，January 31: CBAY ask...查看全文
chuminhua2023-09-08 21:39
9/7，CymaBay Therapeutics $Cymabay Therapeutics(CBAY)$ 的股价周四上涨了 23%，此前该公司报告其在研药物 seladelpar 在原发性胆汁性胆管炎 (PBC) 患者的 III 期研究中实现了主要目标。 该公司表示，RESPONSE 试验数据支持该产品向美国和欧洲监管机构提交上市申请。
RESPONSE 研究将 193 名...查看全文
不入流资讯2023-09-07 20:50
$Cymabay Therapeutics(CBAY)$ CymaBay Therapeutics jumps 25% premarket as its Seladelpar achieved high statistical significance for the primary and key secondary endpoints in the phase 3 response trial查看全文
产业链观察2023-09-07 19:54
#药闻简讯# 2023年9月7日， -- 专注于为肝病和其他慢性疾病患者提供创新疗法的生物制药公司$Cymabay Therapeutics(CBAY)$ 宣布其研究评估了seladelpar的安全性和有效性，seladelpar是一种强效、选择性、口服活性delpar或PPARδ激动剂，正在开发用于治疗成年原发性胆汁性胆管炎（PBC）患者。该注册...查看全文
薛定锷之猫2023-02-21 09:51
$Cymabay Therapeutics(CBAY)$ RESPONSE 7,8能出结果吧？查看全文
产业链观察2023-01-09 04:08
#药闻简讯# 2023年1月8日，$Cymabay Therapeutics(CBAY)$ 今天宣布，已经与Kaken Pharmaceutical Co.("Kaken")达成合作和许可协议，在日本开发和商业化CymaBay的研究性药物seladelpar，用于治疗原发性胆汁性胆管炎（"PBC"）。
根据协议条款，Kaken获得了在日本开发、商业化和...查看全文
薛定锷之猫2022-08-03 10:17
$Cymabay Therapeutics(CBAY)$ 几个疑问：
1、Seladelpar 的专利到什么时候？ 网上搜到说到2035
2、BLACKROCK减仓？还是变更持有人？
3、运营cash不够，面临增发：时机是等file BLA？
4、成交量不够大，与历史相比
看来是潜在候选，但这个2期临床失败怎么回事，还得做功课：ht...查看全文
美股滚雪球2021-10-08 13:06
$Cymabay Therapeutics(CBAY)$ 一家治疗肝脏疾病和慢性病的公司，主要候选药物 seladelpar 正在研究几种主要肝脏疾病的治疗，包括原发性胆汁性胆管炎 (PBC)、非酒精性脂肪性肝炎和原发性硬化性胆管炎。
Seladelpar 是一种口服给药的选择性 PPARdelta 激动剂，获得了FDA的突破性疗法认定和EMEA...查看全文
薛定锷之猫2021-10-07 06:59
$Cymabay Therapeutics(CBAY)$ 貌似接下来的催化剂数据好的可能性高。查看全文
chuminhua2020-11-22 14:40
11/16，CymaBay Therapeutics公司正在使其肝病药物seladelpar重新走上正轨。该疗法在降低原发性胆管炎(PBC)患者的一种肝酶方面击败了安慰剂，这些数据是在该公司停止了该药物的所有临床开发一年后，以及恢复该项目四个月后得出的。
研究终点是碱性磷酸酶（ALP）和胆红素的指标，经过三个月的治...查看全文
$Cymabay Therapeutics(CBAY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-035468 Size: 10 KB 网页链接
$Cymabay Therapeutics(CBAY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-035470 Size: 30 KB 网页链接
$Cymabay Therapeutics(CBAY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-035474 Size: 24 KB 网页链接
$Cymabay Therapeutics(CBAY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-035447 Size: 34 KB 网页链接
$Cymabay Therapeutics(CBAY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-035446 Size: 12 KB 网页链接
$Cymabay Therapeutics(CBAY)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-24-075403 Act: 33 Size: 36 KB 网页链接
$Cymabay Therapeutics(CBAY)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-24-075404 Act: 33 Size: 36 KB 网页链接
$Cymabay Therapeutics(CBAY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-035448 Size: 32 KB 网页链接
$Cymabay Therapeutics(CBAY)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-24-075406 Act: 33 Size: 36 KB 网页链接
$Cymabay Therapeutics(CBAY)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-24-075407 Act: 33 Size: 36 KB 网页链接